Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines
Autore:
Loprevite, M; Favoni, RE; de Cupis, A; Pirani, P; Pietra, G; Bruno, S; Grossi, F; Scolaro, T; Ardizzoni, A;
Indirizzi:
Ist Nazl Ric Canc, Dept Pharmacol, I-16132 Genoa, Italy Ist Nazl Ric CancGenoa Italy I-16132 pt Pharmacol, I-16132 Genoa, Italy Ist Nazl Ric Canc, Dept Med Oncol 1, I-16132 Genoa, Italy Ist Nazl Ric Canc Genoa Italy I-16132 Med Oncol 1, I-16132 Genoa, Italy Ctr Biotecnol Avanzate, Unit Cytometry, I-16132 Genoa, Italy Ctr BiotecnolAvanzate Genoa Italy I-16132 tometry, I-16132 Genoa, Italy Ist Nazl Ric Canc, Dept Radiat Oncol, I-16132 Genoa, Italy Ist Nazl Ric Canc Genoa Italy I-16132 Radiat Oncol, I-16132 Genoa, Italy
Titolo Testata:
LUNG CANCER
fascicolo: 1, volume: 33, anno: 2001,
pagine: 27 - 39
SICI:
0169-5002(200107)33:1<27:IBNAAA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLON-CARCINOMA CELLS; IN-VITRO; HUMAN TUMOR; GEMCITABINE 2',2'-DIFLUORO-2'-DEOXYCYTIDINE; IONIZING-RADIATION; ANTITUMOR-ACTIVITY; TOPOISOMERASE-I; HELA-CELLS; TAXOL; TOPOTECAN;
Keywords:
NSCLC; chemotherapy; radiation; cell-cycle; in vitro;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Favoni, RE Ist Nazl Ric Canc, Dept Pharmacol, Largo R Benzi 10, I-16132 Genoa, Italy Ist Nazl Ric Canc Largo R Benzi 10 Genoa Italy I-16132 , Italy
Citazione:
M. Loprevite et al., "Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines", LUNG CANC, 33(1), 2001, pp. 27-39

Abstract

Integration of chemotherapy and radiation is the standard practice in the management of locally advanced inoperable NSCLC. To assess the biological interaction between third generation chemotherapeutic agents and radiation in non-small cell lung cancer (NSCLC) in vitro, we tested a number of different drugs (paclitaxel, docetaxel, gemcitabine, topotecan, SN-38 and cisplatin) combined with radiation, in lung cancer cell lines. Cellular chemosensitivity was determined, using the semi-automated colorimetric MTT assay, after 48, 72 and 96 h of exposure to increasing drug concentrations, (0.001-100 muM) and radiation doses (100-400 cGy). Cell lines used were the adenocarcinoma (ADK), A-549, and the squamous-cell carcinoma (SCC), LX-I. Cells were pre-treated with anticancer agents at 74, 12 and 0 h before irradiation. Cytofluorimetric cell cycle analysis was performed. A significant S-phase block or a G(2)/M block was seen with gemcitabine and topotecan or paclitaxel pre-treatment, respectively. Apoptosis was seen only after paclitaxel exposure in the A-549 cell line. Despite a similar pattern of cell-kinetic changes induced by chemotherapy pre-treatment in all cell lines, the adenocarcinoma A-549 cell line was not radiosensitized by ally of the anticancer agents tested, whereas synergism was observed in the LX-1 squamous carcinoma cell line, when exposed to gemcitabine, SN-38, topotecan and cisplatin. Paclitaxel, despite a favourable cell cycle effect, was not found to be synergistic with radiotherapy in our experimental model. In conclusion, the observed synergism appears to be dose- and timing-independent and seems to be related to the histological subtype being present in SCC only. Favourable perturbation of the cell cycle is evident with all the new agents tested in both cell types, but was not sufficient to produce synergism with radiation. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 08:50:04